GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma

Belantamab mafodotin accepted for accelerated assessment by the EMA’s Committee for Human Medicinal Products (CHMP)